The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Open accessAbstract
Background & aims Some patients with nonalcoholic fatty liver disease (NAFLD) develop liver-related complications and have higher mortality than other patients with NAFLD. We determined the accuracy of simple, noninvasive scoring systems in identification of patients at increased risk for liver-related complications or death.Methods We performed a retrospective, international, multicenter cohort study of 320 patients diagnosed with NAFLD, based on liver biopsy analysis through 2002 and followed through 2011. Patients were assigned to mild-, intermediate-, or high-risk groups based on cutoff values for 2 of the following: NAFLD fibrosis score, aspartate aminotransferase/platelet ratio index, FIB-4 score, and BARD score. Outcomes included liver-related complications and death or liver transplantation. We used multivariate Cox proportional hazard regression analysis to adjust for relevant variables and calculate adjusted hazard ratios (aHRs).Results During a median follow-up period of 104.8 months (range, 3-317 months), 14% of patients developed liver-related events and 13% died or underwent liver transplantation. The aHRs for liver-related events in the intermediate-risk and high-risk groups, compared with the low-risk group, were 7.7 (95% confidence interval [CI]: 1.4-42.7) and 34.2 (95% CI: 6.5-180.1), respectively, based on NAFLD fibrosis score; 8.8 (95% CI: 1.1-67.3) and 20.9 (95% CI: 2.6-165.3) based on the aspartate aminotransferase/platelet ratio index; and 6.2 (95% CI: 1.4-27.2) and 6.6 (95% CI: 1.4-31.1) based on the BARD score. The aHRs for death or liver transplantation in the intermediate-risk and high-risk groups compared with the low-risk group were 4.2 (95% CI: 1.3-13.8) and 9.8 (95% CI: 2.7-35.3), respectively, based on the NAFLD fibrosis scores. Based on aspartate aminotransferase/platelet ratio index and FIB-4 score, only the high-risk group had a greater risk of death or liver transplantation (aHR = 3.1; 95% CI: 1.1-8.4 and aHR = 6.6; 95% CI: 2.3-20.4, respectively).Conclusions Simple noninvasive scoring systems help identify patients with NAFLD who are at increased risk for liver-related complications or death. NAFLD fibrosis score appears to be the best indicator of patients at risk, based on HRs. The results of this study require external validation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Six retrospective cohort studies on individuals with biopsy-proven MASLD showed that NFS and FIB-4 predict the occurrence of liver-related events (AUROCs from 0.72 to 0.86) and overall mortality (AUROCs from 0.67 to 0.82), 176,177 with a similar or lower accuracy compared to histology.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [176]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,135
Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., & Zwahlen, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60269-x · Cited by 5,219
Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,255
Obesity and Cardiovascular Disease
Lavie, C. J., Milani, R. V., & Ventura, H. O. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.12.068 · Cited by 2,326
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
de Franchis, R. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.06.004 · Cited by 2,291
Schuppan, D., & Afdhal, N. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60383-9 · Cited by 2,089
Research works printed but not linked: 1
- Gedaly, 2012, Rising incidence of nonalcoholic steatoheptitis among patients transplanted for hepatocellular carcinoma in the United States, Hepatology, 56, 40A
Cited by
Sorted by citations
Items 101–200 of 501
Martinou, E., Pericleous, M., Stefanova, I., Kaur, V., & Angelidi, A. M. (2022) · Diagnostics · doi:10.3390/diagnostics12020407 · Cited by 89
Rosso, C., Mezzabotta, L., Gaggini, M., Salomone, F., Gambino, R., Marengo, A., Saba, F., Vanni, E., Younes, R., Saponaro, C., et al. (2015) · Hepatology · doi:10.1002/hep.28287 · Cited by 76
Natural flavonoids: Potential therapeutic strategies for non-alcoholic fatty liver disease
Tan, P., Li, J., Qin, X., & He, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1005312 · Cited by 79
Chang, Y., Ryu, S., Kim, Y., Cho, Y. K., Sung, E., Kim, H., Ahn, J., Jung, H. S., Yun, K. E., Kim, S., et al. (2019) · Hepatology · doi:10.1002/hep.30867 · Cited by 74
The non-invasive assessment of hepatic fibrosis
Gheorghe, G., BUNGAU, S. G., Ceobanu, G., Ilie, M., Bacalbașa, N., Bratu, O. G., Vesa, C. M., Găman, M., & Diaconu, C. C. (2020) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2020.08.019 · Cited by 71
Sumida, Y., Yoneda, M., Tokushige, K., Kawanaka, M., Fujii, H., Yoneda, M., Imajo, K., Takahashi, H., Eguchi, Y., Ono, M., et al. (2021) · Life · doi:10.3390/life11020143 · Cited by 70
Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?
Alkhouri, N., & Feldstein, A. E. (2016) · Metabolism · doi:10.1016/j.metabol.2016.01.013 · Cited by 69
Yoneda, M., Imajo, K., Takahashi, H., Ogawa, Y., Eguchi, Y., Sumida, Y., Yoneda, M., Kawanaka, M., Saito, S., Tokushige, K., et al. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1414-2 · Cited by 69
Gerges, S. H., Wahdan, S. A., Elsherbiny, D. A., & El‐Demerdash, E. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119220 · Cited by 76
Tallino, S., Duffy, M. E., Ralle, M., Cortés, M. P., Latorre, M., & Burkhead, J. L. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.04.009 · Cited by 69
Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV
Verna, E. C. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30120-0 · Cited by 68
Ibáñez, L., Bighelli, F., Usón, C., Gámez, C. C., Fernández‐Carrillo, C., Romero, M., Barreales, M., Perelló, C., Madejón, A., Marcos, A. C., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa355 · Cited by 67
Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis
Wang, J., Malik, N., Yin, M., Smyrk, T. C., Czaja, A. J., Ehman, R. L., & Venkatesh, S. K. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i5.859 · Cited by 64
Jin, J., Zhang, H., Cao, Y., Liu, H., Hua, Q., Li, Y., Zhang, Y., Guo, Y., Wu, N., Zhu, C., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10167-w · Cited by 62
Kim, M. N., Han, J. W., An, J., Kim, B. K., Jin, Y., Kim, S., Lee, M., Lee, H. A., Cho, Y., Kim, H. Y., et al. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0506 · Cited by 65
Tamaki, N., Kurosaki, M., Huang, D. Q., & Loomba, R. S. (2022) · Hepatology Research · doi:10.1111/hepr.13764 · Cited by 62
Masugi, Y., Abe, T., Tsujikawa, H., Effendi, K., Hashiguchi, A., Abe, M., Imai, Y., Hino, K., Hige, S., Kawanaka, M., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1121 · Cited by 60
Nascimbeni, F., Ballestri, S., Machado, M., Mantovani, A., Cortez-Pinto, H., Targher, G., & Lonardo, A. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1415756 · Cited by 56
Chan, W., Mustapha, N. R. N., & Mahadeva, S. (2014) · Hepatology International · doi:10.1007/s12072-014-9596-7 · Cited by 59
Role of the PNPLA3 I148M Polymorphism in Nonalcoholic Fatty Liver Disease and Fibrosis in Korea
Lee, S. S., Byoun, Y.-S., Jeong, S., Woo, B.-H., Jang, E. S., Kim, J., & Kim, H. Y. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3279-z · Cited by 62
Seko, Y., Sumida, Y., Tanaka, S., Mori, K., Taketani, H., Ishiba, H., Hara, T., Okajima, A., Yamaguchi, K., Moriguchi, M., et al. (2014) · Hepatology Research · doi:10.1111/hepr.12456 · Cited by 58
Imaging of nonalcoholic fatty liver disease and its clinical utility
Chartampilas, E. (2018) · HORMONES · doi:10.1007/s42000-018-0012-x · Cited by 58
Chalasani, N., Abdelmalek, M. F., Loomba, R. S., Kowdley, K. V., McCullough, A. J., Dasarathy, S., Neuschwander‐Tetri, B. A., Terrault, N. A., Ferguson, B., Shringarpure, R., et al. (2018) · Liver International · doi:10.1111/liv.13974 · Cited by 60
Non‐invasive fibrosis score for hepatitis delta
Lutterkort, G. L., Wranke, A., Yurdaydın, C., Budde, E., Westphal, M., Lichtinghagen, R., Stift, J., Bremer, B., Hardtke, S., Keskın, O., et al. (2016) · Liver International · doi:10.1111/liv.13205 · Cited by 57
Giangregorio, F., Mosconi, E., Debellis, M. G., Provini, S., Esposito, C., Garolfi, M., Oraka, S., KALOUDI, O., Mustafazade, G., Marín‐Baselga, R., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195880 · Cited by 67
Asrani, S. K. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.07.030 · Cited by 56
The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Gunn, N., & Shiffman, M. L. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.08.006 · Cited by 56
Jung, C., Rhee, E., Kwon, H., Chang, Y., Ryu, S., & Lee, W. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.1.165 · Cited by 55
Liu, S., Wang, J., Wu, S., Niu, J., Zheng, R., Bie, L., Xin, Z., Wang, S., Lin, H., Zhao, Z., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154779 · Cited by 54
The genetic backgrounds in nonalcoholic fatty liver disease
Seko, Y., Yamaguchi, K., & Itoh, Y. (2018) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-018-0841-9 · Cited by 55
Guha, I. N., Harris, R., Berhane, S., Dillon, A., Coffey, L., James, M. W., Cucchetti, A., Harman, D. J., Aithal, G. P., Elshaarawy, O., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.01.042 · Cited by 54
Bradley, C. R., Cox, E. F., Scott, R. A., James, M. W., Kaye, P., Aithal, G. P., Francis, S., & Guha, I. N. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.037 · Cited by 53
Chouhan, S., Singh, S., Athavale, D., Ramteke, P. L., Pandey, V., Joseph, J., Mohan, R., Shetty, P. K., & Bhat, M. K. (2016) · Scientific Reports · doi:10.1038/srep27558 · Cited by 51
Seo, Y., Pοlyzos, S. A., Park, K., & Mantzoros, C. S. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.04.026 · Cited by 54
Banini, B. A., & Sanyal, A. J. (2016) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s18885 · Cited by 52
Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease
Hagström, H., Kechagias, S., & Ekstedt, M. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13343 · Cited by 52
Takahashi, T., Watanabe, T., Shishido, T., Watanabe, K., Sugai, T., Toshima, T., Kinoshita, D., Yokoyama, M., Tamura, H., Nishiyama, S., et al. (2017) · Heart and Vessels · doi:10.1007/s00380-017-1113-1 · Cited by 49
Pereyra, D., Rumpf, B., Ammann, M., Perrodin, S. F., Tamandl, D., Haselmann, C., Stift, J., Brostjan, C., Laengle, F., Beldi, G., et al. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-018-07125-6 · Cited by 49
Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease
Patel, V. A., Sanyal, A. J., & Sterling, R. K. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.006 · Cited by 48
Staufer, K., Dengler, M., Huber, H., Marculescu, R., Stauber, R. E., Lackner, C., Dienes, H., Kivaranovic, D., Schachner, C., Zeitlinger, M. A., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.554 · Cited by 48
Increased liver stiffness in patients with severe sleep apnoea and metabolic comorbidities
Trzépizur, W., Boursier, J., Vaillant, M. L., Ducluzeau, P., Dubois, S. G., Henni, S., Abraham, P., Aubé, C., Calès, P., & Gagnadoux, F. (2018) · European Respiratory Journal · doi:10.1183/13993003.00601-2018 · Cited by 48
Peleg, N., Arbib, O. S., Issachar, A., Cohen‐Naftaly, M., Braun, M., & Shlomai, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202393 · Cited by 47
Siddiqui, M. S., Patidar, K. R., Boyett, S. L., Luketic, V. A., Puri, P., & Sanyal, A. J. (2015) · Liver International · doi:10.1111/liv.13054 · Cited by 47
Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease
Altamirano, J., Qi, Q., Choudhry, S., Abdallah, M., Singal, A. K., Humar, A., Bataller, R. A., Borhani, A. A., & Duarte‐Rojo, A. (2020) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.11.14 · Cited by 45
IGFBP-1 and IGF-I as markers for advanced fibrosis in NAFLD – a pilot study
Hagström, H., Stal, P. I., Hultcrantz, R. W., Brismar, K., & Ansurudeen, I. (2017) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2017.1379556 · Cited by 45
Recent advances in understanding and managing non-alcoholic fatty liver disease
Albhaisi, S. A. M., & Sanyal, A. J. (2018) · F1000Research · doi:10.12688/f1000research.14421.1 · Cited by 44
Liu, A., Xu, C., Liu, Y., Sun, D., Jiang, L., Tang, L., Zhu, P., Chen, S., Liu, W., Wang, X., et al. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17362 · Cited by 44
Current status of fibrosis markers
Patel, K., & Shackel, N. A. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000059 · Cited by 44
Salomone, F., Micek, A., & Godos, J. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080219 · Cited by 44
Lambrecht, J., & Tacke, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.634409 · Cited by 46
Screening strategy for non-alcoholic fatty liver disease
Zhang, S., Mak, L., Yuen, M., & Seto, W. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0336 · Cited by 44
Combined APRI/ALBI score to predict mortality after hepatic resection
Starlinger, P. P., Ubl, D. S., Hackl, H., Starlinger, J., Nagorney, D. M., Smoot, R. L., Habermann, E. B., & Cleary, S. P. (2021) · BJS Open · doi:10.1093/bjsopen/zraa043 · Cited by 43
Arslanow, A., Teutsch, M., Walle, H., Grünhage, F., Lammert, F., & Stokes, C. S. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.28 · Cited by 44
Pοlyzos, S. A., Slavakis, A., Koumerkeridis, G., Katsinelos, P., & Kountouras, J. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0713-1330 · Cited by 43
Xin, Z., Zhu, Y., Wang, S., Liu, S., Xu, M., Wang, T., Lu, J., Chen, Y., Zhao, Z., Wang, W., et al. (2019) · Liver International · doi:10.1111/liv.14322 · Cited by 42
Screening for nonalcoholic fatty liver disease-when, who and how?
Dietrich, C. G., Rau, M., & Geier, A. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i35.5803 · Cited by 44
Pallayová, M., & Taheri, S. (2014) · Clinical Obesity · doi:10.1111/cob.12068 · Cited by 43
Serum fibrosis biomarkers predict death and graft loss in liver transplantation recipients
Bhat, M., Ghali, P., Rollet‐Kurhajec, K. C., Bhat, A., Wong, P. Y. N., Deschênes, M., & Sebastiani, G. (2015) · Liver Transplantation · doi:10.1002/lt.24217 · Cited by 41
Regev, A., Palmer, M., Avigan, M., Dimick‐Santos, L., Treem, W. R., MARCINAK, J. F., Seekins, D. W., Krishna, G., Anania, F. A., Freston, J. W., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15153 · Cited by 41
Abeles, R. D., Mullish, B. H., Forlano, R., Kimhofer, T., Adler, M., Tzallas, A. T., Γιαννακέας, Ν., Yee, M. S., Mayet, J., Goldin, R. D., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15192 · Cited by 41
Johnson, A. L., Hayward, K. L., Patel, P. J., Horsfall, L. U., Cheah, A. E. Z., Irvine, K. M., Russell, A. W., Stuart, K. A., Williams, S. R., Härtel, G., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1852 · Cited by 41
Serum biomarkers for liver fibrosis
Chen, Z., Ma, Y., Cai, J., Sun, M., Zeng, L., Wu, F., Zhang, Y., & Hu, M. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.09.022 · Cited by 40
Gaps in Recognition and Evaluation of Incidentally Identified Hepatic Steatosis
Wright, A. P., Desai, A. P., Bajpai, S., King, L. Y., Sahani, D. V., & Corey, K. E. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3346-5 · Cited by 40
Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence
Pang, Q. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i18.5607 · Cited by 40
Long, M. T., Pedley, A., Massaro, J. M., Hoffmann, U., & Fox, C. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157517 · Cited by 40
Cueto-Galán, R., Barón-López, F. J., Valdivielso, P., Pintó, X., Corbella, E., Gómez‐Gracia, E., & Wärnberǵ, J. (2017) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2017.04.030 · Cited by 40
Liu, H., Cao, Y., Jin, J., Hua, Q., Li, Y., Guo, Y., Zhu, C., Wu, N., Gao, R., & Li, J. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.018869 · Cited by 40
Williams, K., de Ribeiro, A. J. V., Prakoso, E., Veillard, A.-S., Shackel, N. A., Bu, Y., Brooks, B. A., Cavanagh, E., Raleigh, J., McLennan, S. V., et al. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.02.024 · Cited by 39
Bertot, L. C., Vilar‐Gómez, E., Wong, V. W., Romero‐Gómez, M., la Fuente, R. A., Wong, G. L., Castellanos, M., Eslam, M., Desai, A. P., Jeffrey, G. P., et al. (2020) · Hepatology · doi:10.1002/hep.31576 · Cited by 39
Barchetta, I., Ceccarelli, V., Cimini, F. A., Barone, E., Sentinelli, F., Coluzzi, M., Chiappetta, C., Bertoccini, L., Tramutola, A., Labbadia, G., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01392-5 · Cited by 37
Non-invasive diagnosis and staging of non-alcoholic fatty liver disease
Kechagias, S., Ekstedt, M., Simonsson, C., & Nasr, P. (2022) · Hormones · doi:10.1007/s42000-022-00377-8 · Cited by 39
Cuthbertson, D. J., Keating, S. E., Pugh, C. J. A., Owen, P. J., Kemp, G. J., Umpleby, M., Geyer, N. G., Chinchilli, V. M., & Stine, J. G. (2024) · Liver International · doi:10.1111/liv.15947 · Cited by 38
Kogiso, T., Sagawa, T., Kodama, K., Taniai, M., Hashimoto, E., & Tokushige, K. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14989 · Cited by 40
Park, H. E., Lee, H., Choi, S., Kim, H. S., & Chung, G. E. (2020) · Scientific Reports · doi:10.1038/s41598-020-61750-4 · Cited by 37
Okamura, Y., Ashida, R., Yamamoto, Y., Ito, T., Sugiura, T., & Uesaka, K. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5377-y · Cited by 37
van Son, K. C., Nijenhuis-Noort, L. C. T., Boone, S. C., Mook-Kanamori, D. O., Holleboom, A. G., Roos, P. R., Lamb, H. J., Alblas, G., Coenraad, M. J., Rosendaal, F. R., et al. (2024) · Medicine · doi:10.1097/md.0000000000034934 · Cited by 36
Noninvasive characterization of graft steatosis after liver transplantation
Karlas, T., Kollmeier, J., Böhm, S. K., Müller, J., Kovacs, P. L., Tröltzsch, M., Weimann, A., Bartels, M. J., Rosendahl, J., Mössner, J., et al. (2014) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2014.983156 · Cited by 36
Kimura, T., Kobayashi, A., Tanaka, N., Sano, K., Komatsu, M., Fujimori, N., Yamazaki, T., Shibata, S., Ichikawa, Y., Joshita, S., et al. (2017) · Hepatology Research · doi:10.1111/hepr.12762 · Cited by 36
Bugianesi, E., Rosso, C., & Cortez‐Pinto, H. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.038 · Cited by 36
Yamamura, S., Kawaguchi, T., Nakano, D., Tomiyasu, Y., Yoshinaga, S., Doi, Y., Takahashi, H., Anzai, K., Eguchi, Y., Torimura, T., et al. (2019) · Hepatology Research · doi:10.1111/hepr.13436 · Cited by 36
Solfrizzi, V., Scafato, E., Custodero, C., Loparco, F., Ciavarella, A., Panza, F., Seripa, D., Imbimbo, B. P., Lozupone, M., Napoli, N., et al. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12065 · Cited by 36
Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.04.028 · Cited by 70
Dichtel, L. E., Corey, K. E., Haines, M. S., Chicote, M. L., Kimball, A., Colling, C., Simon, T. G., Long, M. T., Husseini, J. S., Bredella, M. A., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac405 · Cited by 36
A roadmap for clinical trials in MASH-related compensated cirrhosis
Pericàs, J. M., Anstee, Q. M., Augustín, S., Bataller, R. A., Berzigotti, A., Ciudin, A., Francque, S., Abraldeṣ, J. G., Hernández–Gea, V., Pons, M., et al. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00955-8 · Cited by 38
Song, Z., Miao, X., Liu, S., Hu, M., Xie, X., Sun, Y., & Leng, S. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02716-6 · Cited by 35
Hydes, T., Kennedy, O. J., Glyn‐Owen, K., Buchanan, R. M., Parkes, J., Cuthbertson, D. J., Roderick, P., & Byrne, C. D. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.03.045 · Cited by 35
Krishnamurthy, V. N., Zhāng, P., Ethiraj, S., Enchakalody, B. E., Waljee, A. K., Wang, L., Wang, S. C., & Su, G. L. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.07.042 · Cited by 34
TINIAKOS, D. G., Anstee, Q. M., & Burt, A. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6697-9.00005-4 · Cited by 35
Dai, H., Xiang, J., Hou, Y., Xuan, L., Wang, T., Li, M., Zhao, Z., Xu, Y., Lu, J., Chen, Y., et al. (2021) · Nutrition & Metabolism · doi:10.1186/s12986-021-00551-6 · Cited by 34
Screening for Liver Fibrosis in the General Population: Where Do We Stand in 2022?
Canivet, C. M., & Boursier, J. (2022) · Diagnostics · doi:10.3390/diagnostics13010091 · Cited by 35
Tian, Y.-B., Niu, H., Xu, F., Shang-Guan, P.-W., & Song, W.-W. (2024) · Scientific Reports · doi:10.1038/s41598-024-58205-5 · Cited by 33
Xun, Y., Guo, J., Lou, G., Jiang, Y., Zhuang, Z., Zhu, M., Luo, Y., Ma, X., Liu, J., Bian, D., et al. (2014) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12260 · Cited by 33
Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.04.029 · Cited by 34
Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions
Motola, D., Caravan, P. D., Chung, R. T., & Fuchs, B. C. (2014) · Current Pathobiology Reports · doi:10.1007/s40139-014-0061-z · Cited by 33
Cueto-Galán, R., Barón-López, F. J., Valdivielso, P., Pintó, X., Corbella, E., Gómez‐Gracia, E., & Wärnberǵ, J. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2016.11.032 · Cited by 35
Wang, Y., Song, S. J., Jiang, Y., Lai, J. C., Wong, G. L., Wong, V. W., & Yip, T. C. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0246 · Cited by 32
Pavlik, L., Regev, A., Ardayfio, P. A., & Chalasani, N. (2019) · Drug Safety · doi:10.1007/s40264-018-00790-2 · Cited by 32
Non-invasive assessment of liver fibrosis and prognosis
Hagan, M. E., Asrani, S. K., & Talwalkar, J. A. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1075391 · Cited by 32
Golabi, P., Stepanova, M., Pham, H. T., Cable, R., Rafiq, N., Bush, H., Gogoll, T., & Younossi, Z. M. (2018) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2018-000198 · Cited by 32
Metadata
- Authors
- Angulo, P., Bugianesi, E., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Barrera, F., Haflidadottir, S., Day, C. P., & George, J.
- Affiliations
- University of Kentucky HealthCare (US)
- University of Turin (IT)
- National University Hospital of Iceland (IS)
- Siriraj Hospital (TH)
- Gartnavel General Hospital (GB)
- Newcastle University (GB)
- The University of Sydney (AU)
- Corresponding author
- Angulo, Paul
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 145
- Issue
- 4
- Pages
- 782-789.e4
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC3931256
- OpenAlex
- W2129639561
- Cited by
- 502
- References
- 32
- Citations by year
- 2026: 7 · 2025: 29 · 2024: 31 · 2023: 32 · 2022: 46 · 2021: 60 · 2020: 49 · 2019: 40 · 2018: 39 · 2017: 35 · 2016: 36 · 2015: 49 · 2014: 45 · 2013: 4
- FWCI
- 32.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- National Institutes of Health (R01 DK82426)
- Seventh Framework Programme (HEALTH-F2-2009-241762)
- National Health and Medical Research Council (1049857, 632630)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, NAFLD fibrosis score, FIB-4, BARD score, liver complications, mortality, liver transplantation, disease progression, prognosis, liver fibrosis, risk stratification, prognostic accuracy
- MeSH terms
- Adult, Fatty Liver, Female, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, Cohort Studies, Kaplan-Meier Estimate, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
